Vivera is inviting AbbVie’s Allergan to collaborate on its high-tech medical device, ZICOH, designed to end addiction, in light of the former opioid maker’s recently proposed $2.37 billion settlement for its alleged role in the opioid crisis.
State and local governments sued Allergan, claiming the company deceptively marketed opioids by downplaying the risk of addiction and exaggerating the benefits. In addition, the lawsuits allege that Allergan allegedly failed to maintain adequate controls to prevent the diversion of its opioid-based medications.
Alongside several major companies suing for close to $38 billion, the proposed settlement would require Allergan to pay $2.37 billion over six years to resolve more than 2,500 opioid-related lawsuits filed by state and local governments and tribes across the country affected by the crisis.
Vivera argues that while it is critical to provide resources to states and communities that have already been affected by the opioid crisis, it is equally important to take steps to prevent future addiction. Vivera invented ZICOH, a patented, dose-controlled, cloud-connected electronic prescription drug delivery system, to help combat the opioid crisis by preventing prescription drug misuse, abuse and diversion.
“Vivera developed ZICOH to end prescription drug addiction,” said Paul Edalat, Chairman and CEO of Vivera. “Opioids have taken enough lives and it’s time for a solution. ZICOH involves the entire drug supply chain, making it the ideal solution.”
This invitation comes just one week after Vivera invited Teva Pharmaceuticals to collaborate in the development of ZICOH after the company announced its $4.35 billion settlement proposal for its alleged role in the opioid crisis.
In addition to Teva and Allergan, Vivera has also contacted other companies that have proposed or accepted settlement agreements for their alleged role in the ongoing opioid crisis. The list includes the following companies and their agreed payments:
Mr Edalat added: “We see these big companies visiting our website, so we know who has received our message. We are just waiting for the companies that share Vivera’s vision to end addiction to lean in and collaborate on the commercialization of ZICOH. We look forward to starting a conversation about how to end the opioid crisis with these major players in the pharmaceutical supply chain.”
Vivera Pharmaceuticals is an innovative, science-driven pharmaceutical company located in Southern California. The company has global exclusivity to license the patented and patent-pending TABMELT sublingual drug delivery system for pharmaceutical use and has its own issued patents on ZICOH, a smart dose-controlled electronic medical device. The company has also received a notice of approval for its portable telemedicine station, MDZone. With multiple divisions, including the Pharmaceutical, Neuroscience, Medical Technology, Life Sciences and Advanced Diagnostics divisions, Vivera Pharmaceuticals is vertically integrated with patented technology, manufacturing capabilities and distribution for its products.
For more information, visit viverapharmaceuticals.com or connect with us on LinkedIn, Facebook, Twitter or Instagram.
